BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Cipla
Accenture
Citi
Harvard Business School
Mallinckrodt
Medtronic
Novartis
US Army
Daiichi Sankyo

Generated: January 22, 2018

DrugPatentWatch Database Preview

BESIVANCE Drug Profile

« Back to Dashboard

When do Besivance patents expire, and when can generic versions of Besivance launch?

Besivance is a drug marketed by Bausch And Lomb and is included in one NDA. There are six patents protecting this drug.

This drug has fifty-three patent family members in nineteen countries.

The generic ingredient in BESIVANCE is besifloxacin hydrochloride. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the besifloxacin hydrochloride profile page.
Summary for BESIVANCE
International Patents:53
US Patents:6
Applicants:1
NDAs:1
Suppliers / Packagers: 3
Bulk Api Vendors: 37
Clinical Trials: 12
Patent Applications: 13
Drug Prices:see details
DailyMed Link:BESIVANCE at DailyMed
Drug patent expirations by year for BESIVANCE
Pharmacology for BESIVANCE
Ingredient-typeQuinolones
Drug ClassQuinolone Antimicrobial

US Patents and Regulatory Information for BESIVANCE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb BESIVANCE besifloxacin hydrochloride SUSPENSION/DROPS;OPHTHALMIC 022308-001 May 28, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Bausch And Lomb BESIVANCE besifloxacin hydrochloride SUSPENSION/DROPS;OPHTHALMIC 022308-001 May 28, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bausch And Lomb BESIVANCE besifloxacin hydrochloride SUSPENSION/DROPS;OPHTHALMIC 022308-001 May 28, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Bausch And Lomb BESIVANCE besifloxacin hydrochloride SUSPENSION/DROPS;OPHTHALMIC 022308-001 May 28, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bausch And Lomb BESIVANCE besifloxacin hydrochloride SUSPENSION/DROPS;OPHTHALMIC 022308-001 May 28, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Bausch And Lomb BESIVANCE besifloxacin hydrochloride SUSPENSION/DROPS;OPHTHALMIC 022308-001 May 28, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for BESIVANCE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,239,113 Topical treatment or prevention of ocular infections ➤ Subscribe
7,749,970 Topical treatment of prevention of ocular infections ➤ Subscribe
6,569,443 Topical treatment or prevention of ocular infections ➤ Subscribe
7,056,893 Topical treatment for prevention of ocular infections ➤ Subscribe
7,732,415 Topical treatment or prevention of ocular infections ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for BESIVANCE

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Healthtrust
Merck
Cerilliant
Chubb
Moodys
Federal Trade Commission
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot